ClinConnect ClinConnect Logo
Search / Trial NCT06535178

The Influence of Sleep on Cardiovascular Outcomes

Launched by OREGON HEALTH AND SCIENCE UNIVERSITY · Jul 31, 2024

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

Circadian Rhythm Cardiometabolic Health Vascular Health

ClinConnect Summary

This clinical trial is looking at how sleep patterns affect heart health. Researchers want to find out if having a regular sleep schedule can lead to better metabolic and vascular health, which relates to how our bodies manage energy and blood flow. The study will last for 12 weeks and will involve both in-home and lab assessments. They are currently recruiting healthy adults aged 18 to 40, both men and women, to participate in this important research.

To be eligible, participants must be generally healthy and cannot have a history of substance abuse, smoking, or certain medical conditions like heart disease, high blood pressure, diabetes, or sleep disorders. They should also not have worked irregular hours or traveled across time zones in the months leading up to the study. Those who choose to participate can expect to contribute to our understanding of how sleep impacts heart health, helping to improve health recommendations for everyone in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • - Ostensibly healthy men and women
  • Exclusion Criteria:
  • No history of drug or alcohol dependency.
  • Must be current non-smokers, and are required to have a history of less than 5 pack years of smoking.
  • No history of working irregular day and night hours, regular night work, or rotating shift work for the 1 year prior to the study. In addition to this, individuals must not have traveled across more than 1 time zone during the 3 months prior to the study.
  • Chronobiologic and sleep disorders.
  • Diseases of the cardiovascular system.
  • Hypertension. Individuals will be allowed to be normotensive (resting systolic blood pressure of \<140/90 mmHg, measured on more than one occasion) or uncomplicated stage 1 hypertension (systolic BP between 140 and 159 mmHg or a diastolic BP between 90 and 99 mmHg).
  • Disorders of the respiratory system.
  • Pre-diabetes/Diabetes. For participants who have self-reported pre-diabetes/diabetes.
  • Disorders of the kidney and urinary tract.
  • Infectious diseases.
  • Disorders of the gastrointestinal system.
  • Disorders of the immune system.
  • Disorders of the hematopoietic system.
  • Neoplastic diseases.
  • Endocrine and metabolic diseases.
  • Neurologic disorders.
  • Must not be participating in another research study that would influence their safe participation in the study.

About Oregon Health And Science University

Oregon Health and Science University (OHSU) is a leading academic medical center dedicated to advancing health through research, education, and patient care. As a prominent sponsor of clinical trials, OHSU leverages its extensive expertise in various medical fields to facilitate innovative research aimed at improving patient outcomes. The institution is committed to ethical standards and rigorous scientific methodologies, fostering collaborations that enhance the development of new therapies and interventions. With a focus on translating research discoveries into clinical practice, OHSU plays a pivotal role in shaping the future of healthcare.

Locations

Portland, Oregon, United States

Patients applied

KR

1 patients applied

Trial Officials

Andrew W McHill, PhD

Principal Investigator

Oregon Health and Science University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported